Mission Therapeutics Strengthens Clinical Development Team with Appointment of Dr Judit Molnar as Senior Director, Translational Medicine
CAMBRIDGE, UK – 4 September 2018 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat mitochondrial diseases, fibrosis, neurodegenerative and other diseases, today announced the appointment of Dr Judit Molnar, MD, PhD to Senior Director of Translational Medicine with immediate effect.
Judit has over ten years of experience in translational science and early drug development of which nine years were spent working in the pharmaceutical industry. She has led small molecule drug development programmes across a variety of therapeutic areas including inflammation and fibrotic disorders, which have resulted in lead candidates being progressed from the preclinical stage into the clinic up to Phase II.
Commenting on the appointment, Dr Paul Thompson, Vice President, Clinical Development at Mission said:
“We are pleased to welcome Judit to Mission’s clinical leadership team. Judit’s in-depth clinical knowledge and proven drug development track record will further strengthen our team as we work to translate scientific advances in the DUB field into transformative therapeutics for mitochondrial diseases and fibrosis.
“She joins Mission at an opportune moment as we have just selected a lead candidate inhibitor for our USP30 programme in mitochondrial diseases and fibrosis. Her expertise and insights will prove invaluable as we progress this programme towards clinical studies during 2019.”
Dr Judit Molnar, newly appointed Senior Director, Translational Medicine, Mission Therapeutics, said:
“Mission’s unique science, chemistry and DUB platform, applicable across numerous therapeutic areas with high unmet need, is highly impressive. I am looking forward to working alongside the experienced and dedicated leadership team to advance its ambitious USP30 and other programmes through preclinical and into clinical development.”
Judit joins Mission from GlaxoSmithKline where she was Preclinical Biology Lead in Epigenetics in immuno-inflammation before being promoted to Director of Translational Medicine in 2016. Prior to this she worked from 2008 at Pfizer as a Drug Discovery Scientist and Daphne Jackson Research Fellow. Previously, she was a Research Fellow at Mount Sinai School of Medicine, New York, USA. Judit obtained a PhD in Physiology from Cornell University, New York, USA and completed her medical degree at the Semmelweis University, Budapest, Hungary.
Issued for and on behalf of Mission Therapeutics by Instinctif Partners.
For more information please contact:
At Mission Therapeutics Ltd:
Anker Lundemose MD PhD
Chief Executive Officer
T: +44 (0) 1223 607340
At Instinctif Partners:
Melanie Toyne-Sewell / Eileen Paul / Priya Kalia
T: +44 (0) 20 7457 2020
- ENDS -
Notes To Editors
About Mission Therapeutics
Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of neurodegenerative disease, rare mitochondrial diseases, fibrosis and inflammation. The Company has built a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.
Mission has strong links with key academic and research centers, including Prof. Jackson’s Cancer Research UK Laboratories at the University of Cambridge Gurdon Institute, and leading UK centres in neurodegenerative diseases. The Company is managed by a team with broad international, commercial and clinical-science experience.
In February 2016, the Company completed an $86m financing that was led by Imperial Innovations (now part of IP Group) and Woodford Patient Capital Trust and included participation from existing investors Sofinnova Partners, Roche Venture Fund, Pfizer Venture Investments and SR One. Mission Therapeutics was founded in 2011 and is based at the Babraham Research Campus, Cambridge, UK.